Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06101277` - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)	N/A
Completed	`NCT02626195` - Preoperative Nutritional Support in Malnutritional Cancer Patients	N/A
Completed	`NCT01401894` - Perception Prognosis, Goals of Treatment, and Communication	N/A
Completed	`NCT00551096` - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT04517448` - Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
Recruiting	`NCT04644068` - Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05849480` - A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)	Phase 1/Phase 2
Completed	`NCT02703714` - Pembrolizumab and GM-CSF in Biliary Cancer	Phase 2
Completed	`NCT01853618` - Tremelimumab With Chemoembolization or Ablation for Liver Cancer	Phase 1/Phase 2
Recruiting	`NCT05462314` - Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
Recruiting	`NCT05517811` - Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Active, not recruiting	`NCT01661114` - A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	Phase 2
Recruiting	`NCT01859728` - GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer	Phase 2
Withdrawn	`NCT04480190` - Neoadjuvant Therapy in Biliary Adenocarcinoma	Phase 1
Completed	`NCT00626158` - Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers	Phase 1
Terminated	`NCT04566133` - Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	Phase 2
Completed	`NCT02930252` - Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.	N/A
Recruiting	`NCT02628067` - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Phase 2
Terminated	`NCT00868998` - GTX Regimen for Biliary Cancers	Phase 2
Terminated	`NCT02908451` - A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer	Phase 1

NCT number	NCT01773785
Study type	Interventional
Source	Spectrum Pharmaceuticals, Inc
Contact
Status	Terminated
Phase	Phase 2
Start date	April 2013
Completion date	September 2015

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms